New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
13:30 EDTBCRX, DYAXBioCryst data has favorable read through for Dyax, says Jefferies
After Biocryst (BCRX) reported positive data from a trial evaluating BCX4161 in hereditary angioedema, Jefferies said the study results point to higher odds for the success of Dyax's (DYAX) DX-2930, which has a similar pathway and is being developed as a prophylactic treatment for HAE. The firm maintains its Buy rating and $13.00 price target on Dyax.
News For DYAX;BCRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
15:14 EDTBCRXTraveler returned from Mali being tested for Ebola in NYC, Daily News reports
Subscribe for More Information
November 17, 2014
08:44 EDTBCRXNebraska Medical announces death of third Ebola patient
The Nebraska Medical Center said via Twitter, "We are sorry to announce that the 3rd Ebola patient, Dr. Martin Salia, has passed away as a result of the advanced symptoms of the disease." Drug companies that are working on experimental Ebola vaccines or treatments include Peregrine (PPHM), Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Some companies that offer protective clothing and waste disposal include Lakeland Industries (LAKE), Alpha Pro Tech (APT) and Sharps Compliance (SMED).
November 14, 2014
16:23 EDTDYAXDyax files automatic mixed securities shelf
Subscribe for More Information
November 13, 2014
10:42 EDTDYAXSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use